MDT-AP-0757
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 24
- os_event
- false
- age_years
- 7
- sex
- M
- new_clusters
- C1
- umap1_2d
- 4.722940051
- umap2_2d
- 1.073251656
- umap1_3d
- 0.710344955
- umap2_3d
- -3.189415491
- umap3_3d
- -1.840658127
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.200
- HEME_METABOLISM+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.140
- MYOGENESIS+0.130
- APICAL_JUNCTION+0.120
- WNT_BETA_CATENIN_SIGNALING+0.100
- FATTY_ACID_METABOLISM+0.090
- KRAS_SIGNALING_DN+0.090
- PEROXISOME+0.070
- BILE_ACID_METABOLISM+0.040
Top 10 suppressed
- E2F_TARGETS-0.690
- G2M_CHECKPOINT-0.620
- MYC_TARGETS_V1-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- ANGIOGENESIS-0.430
- MYC_TARGETS_V2-0.400
- ALLOGRAFT_REJECTION-0.320
- COMPLEMENT-0.310
- INFLAMMATORY_RESPONSE-0.300
- MTORC1_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0852 | Med | Medulloblastoma | 0.898 |
| 2 | MDT-AP-0838 | Med | Medulloblastoma | 0.860 |
| 3 | MDT-AP-0343 | Med | Medulloblastoma | 0.848 |
| 4 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.840 |
| 5 | MDT-AP-0405 | Med | Medulloblastoma | 0.834 |
| 6 | MDT-AP-0381 | Med | Medulloblastoma | 0.833 |
| 7 | BS_ERWT0ZWE | Med | Medulloblastoma | 0.826 |
| 8 | BS_55P8HPYD | pilocytic astrocytoma | — | 0.825 |
| 9 | MDT-AP-0393 | Med | Medulloblastoma | 0.823 |
| 10 | MDT-AP-0009 | Med | Medulloblastoma | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.040 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |